ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 i

A

admin

Administrator
Jun 17, 2007
66,216
0
36
49
Canada
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide ORIC-101 plasma concentrations provided excellent target coverage, consistent suppression of key glucocorticoid receptor (GR) biomarkers, and no evidence of drug-drug interaction impacting enzalutamide The addition of ORIC-101 after progression on single agent enzalutamide enabled continued enzalutamide treatment, with preliminary ev
 
You must log in or register to reply here.
Back
Top